Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
The purpose of this study is to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). The study will determine the safety in participants that receive nivolumab when given in combination with daratumumab, with or without pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Relapsed and/or refractory multiple myeloma
Relapsed and/or refractory multiple myeloma patients who have had at least 2 prior lines of therapy, including 2 consecutive cycles of each immunomodulatory agent (IMiD, such as lenalidomide or thalidomide) and a proteasome inhibitor (PI, such as bortezomib or carfilzomib) alone or in combination.
18 - 99
Healthy Volunteers Needed
Duration of Participation
The duration of your participation will depend on your response to treatment. After completing all study treatments or after you are withdrawn from treatment, you will be asked to continue with follow-up visits to monitor for side effects or potential benefits you may be experiencing from study treatment. Your total participation in this study from the time you have signed the informed consent form through your last visit may be a maximum of 5 years.
Clinical Trials Information Line